JCR Pharmaceuticals Co., Ltd. announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo®?, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease. The achievement of a predefined research milestone triggers a milestone payment to JCR. JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
806 JPY | -0.86% | +1.13% | -31.23% |
Apr. 25 | JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024 | CI |
Mar. 21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.23% | 658M | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion